PARP1 and sarcoma: For samples profiled by WES, we examined sarcoma genomes for an HRD phenotype, often associated with DDR pathway alterations in various cancer types, by calculating a GSS that is predictive of poly adenosine diphosphate-ribose polymerase (PARP) inhibitor sensitivity [20].